# ACE-536-MF-001 (NCT03194542)

> A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03194542
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Primary Myelofibrosis; Anemia
- Interventions: Luspatercept
- Enrollment: 95
- Primary outcome: The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period

## Indexed commentary on ACE-536-MF-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ace-536-mf-001-nct03194542

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03194542", "email": "<work email>"}; the inbox owner confirms by the emailed link.